+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

KOL Perspectives: Treatment strategies for pregnant RA patients

  • PDF Icon

    Drug Pipelines

  • 27 Pages
  • July 2018
  • Region: Global
  • GlobalData
  • ID: 4701803
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.


This KOL Insight briefing focuses on KOLs views of Treatment strategies for pregnant RA patients.

Questions topics -
  • Current views on suitable therapies to treat pregnant RA patients

  • Certolizumab -use in pregnant RA patients

  • Other anti-TNFs -use in pregnant RA patients

  • IL-6 inhibitors -use in pregnant RA patients

  • Abatacept -use in pregnant RA patients

  • JAK inhibitors -use in pregnant RA patients

Key Highlights
  • Majority of KOLs currently use anti-TNFs for treating pregnant RA patients, with a marked preference for certolizumab

  • No consensus among KOLs on the use of IL-6 inhibitors during pregnancy, although monotherapy use was not considered an advantage

  • Majority of KOLs were averse to prescribing JAK inhibitors during pregnancy, primarily due to the lack of any data in this setting.

  • The insight briefing is based on Sociable Pharma’s analysis of primary research with our RA key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs -
  • 5 Europe-based & 5 N. America-based

  • Interviews performed during Apr 2018

KOL data is analyzed to produce -
  • Charts summarizing KOL opinions

  • Chart call-outs of key information & details

  • KOL quotes

  • Summary of KOL reporting trends

  • Insight from Sociable Pharma's analysts

Reasons to Buy
  • Combines Qualitative & semi-quantitative insight from key opinion leaders on Treatment strategies for pregnant RA patients

  • Includes insight & recommendations from our disease-specific healthcare analysts

  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of RA

  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Table of Contents

  • Executive Summary

  • Background

  • Research Panel Composition

  • Results & Implications

  • Appendix



Companies Mentioned

A selection of companies mentioned in this report includes:

  • UCB

  • AbbVie

  • Janssen

  • Roche

  • Sanofi

  • Regeneron

  • BMS